About Us

Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Our commitment to leveraging nanotechnology and transforming patients' lives is demonstrated through the alignment of scientific rigor and innovation for the future.

At Mosaic, our core values of respect and trust provide a strong foundation for discovering and developing innovative medicines for human and animal health.

Power of the Cowpea mosaic virus (CPMV) Platform
Cancer Immunotherapy

While CPMV is non-infectious toward mammals, it is immunogenic. The repetitive, multivalent protein assemblies are pathogen-associated molecular patterns (PAMPs) that act as danger signals and activate the innate immune system. The primary PAMP receptors that recognize proteins are Toll-like receptors (TLRs).
 

CPMV intratumoral immunotherapy against tumors 
When administered directly into an identified tumor, the immune-stimulation by CPMV recruits innate immune cells into the tumor microenvironment triggering a cascade of events that leads to systemic and durable anti-tumor immunity and immune memory.  
CPMV infected Cowpea Plant
CPMV-based platform against emerging infectious diseases
CPMV acts as an adjuvant and can be engineered to display and deliver antigens to the immune system, eliciting potent anti-viral immune responses against the target pathogen.
Vaccine platform technology
Based on their immune-stimulatory properties and their size, virus-like nanoparticles are ideal for the delivery of subunit vaccines to the draining lymph nodes where they stimulate antigen processing by antigen-presenting cells (APCs). The virus-like nanoparticle system is more than just a delivery platform; it also acts as an adjuvant that stimulates the immune system. The technology uses a plug-and-play approach where antigen targets can easily be exchanged as mutations, new strains, and/or novel infectious disease pathogens emerge.
  • The platform is based on the CPMV nanoparticle (Core Development Molecule). 

  • By using a single core base, development activities can be streamlined. 

  • This approach also allows Mosaic IE to simultaneously move multiple programs forward, designed to meet unmet medical needs.

Current Programs

© 2020 by Mosaic ImmunoEngineering Inc.